Control of modifiable risk factors in ischemic stroke outpatients by pharmacist intervention: An equal allocation stratified randomized study

Journal of Clinical Pharmacy and Therapeutics

Volumn 33, Issue 5, 2008, Pages 529-535

  Chiu, Chun Chi ^b   Wu, Shin Sheng ^c   Lee, Ping Yi ^b   Huang, Yu Ching ^b   Tan, Teng Yeow ^b,d   Chang, Ku Chou ^a,b,d  

^a Chang Gung Memorial Hospital ^*  (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Pharmacist intervention; Risk factors; Stroke care

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; INSULIN; MEGLITINIDE; SIMVASTATIN; SULFONYLUREA; WARFARIN;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG UTILIZATION; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH EDUCATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PHARMACIST; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

AGED; AMBULATORY CARE; BLOOD GLUCOSE; BLOOD PRESSURE; BRAIN ISCHEMIA; CATCHMENT AREA (HEALTH); FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; OUTPATIENT CLINICS, HOSPITAL; PHARMACISTS; PHARMACY SERVICE, HOSPITAL; PROFESSIONAL ROLE; RISK FACTORS; STROKE; TAIWAN;

EID: 52049107159     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.00940.x     Document Type: Article

References (30)

1. ISH Writing Group (2003) International Society of Hypertension (ISH): statement on blood pressure lowering and stroke prevention. Journal of Hypertension, 21, 651 663.
2. Berthiaume JT, Davis J, Taira DA, Thein KK (2007) A managed care organization's use of integrated health management to improve secondary prevention of coronary artery disease. American Journal of Managed Care, 13, 142 147.
3. Godley PJ, Maue SK, Farrelly EW, Frech F (2005) The need for improved medical management of patients with concomitant hypertension and type 2 diabetes mellitus. American Journal of Managed Care, 11, 206 210.
4. Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, Schwartz JS Predictors of adherence with antihypertensive and lipid-lowering therapy. Archives of Internal Medicine, 165, 1147 1152.
5. Schwiesow SJ, Nappi JM, Ragucci KR (2006) Assessment of compliance with lipid guidelines in an academic medical center. Annals of Pharmacotherapy, 40, 27 31.
6. Goldstein MK, Lavori P, Coleman R, Advani A, Hoffman BB (2005) Improving adherence to guidelines for hypertension drug prescribing: cluster-randomized controlled trial of general versus patient-specific recommendations. American Journal of Managed Care, 11, 677 685.
7. Olson KL, Rasmussen J, Sandhoff BG, Merenich JA (2005) Clinical Pharmacy Cardiac Risk Service (CPCRS) Study Group. Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization. Archives of Internal Medicine, 165, 49 54.
8. John EJ, Vavra T, Farris K et al. (2006) Workplace-based cardiovascular risk management by community pharmacists: impact on blood pressure, lipid levels, and weight. Pharmacotherapy, 26, 1511 1517.
9. Cote I, Moisan J, Chabot I, Gregoire JP (2005) Health-related quality of life in hypertension: impact of a pharmacy intervention programme. Journal of Clinical Pharmacy and Therapeutics, 30, 355 362.
10. McConnell KJ, Zadvorny EB, Hardy AM, Delate T, Rasmussen JR, Merenich JA (2006) Coronary artery disease and hypertension: outcomes of a pharmacist-managed blood pressure program. Pharmacotherapy, 26, 1333 1341.
11. Bottorff M (2006) Role of the pharmacist. Pharmacotherapy, 26, 227S 232S.
12. Chang KC, Tseng MC, Tan TY (2002) Prediction of length of stay of first-ever ischemic stroke. Stroke, 33, 2670 2674.
13. Chang KC, Tseng MC (2003) Costs of acute care of first-ever ischemic stroke in Taiwan. Stroke, 34, e219 e221.
14. Tan TY, Chang KC, Liou CW, Schminke U (2005) Prevalence of carotid artery stenoses in Taiwanese patients with one ischemic stroke. Journal of Clinical Ultrasound, 33, 1 4.
15. Tan TY, Chang KC, Tseng MC (2004) Risk factors for first-ever ischemic stroke: a hospital-based case-control study in Kaohsiung, Taiwan. Chang Gung Medical Journal, 27, 801 807.
16. Chang KC, Tseng MC, Tan TY (2004) Prehospital delay after acute stroke in Taiwan. Stroke, 35, 700 704.
17. Chobanian AV, Bakris GL, Black HR, Materson BJ, Wright JT, Roccella EJ (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA, 289, 2560 2572.
18. American Diabetes Association (2006) Standards of medical care in diabetes-2006. Diabetes Care, 29, S4 S42.
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 2001) Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel (III). JAMA, 285, 2486 2497.
20. Peterson GM, Fitzmaurice KD, Naunton M, Vial JH, Stewart K, Krum H (2004) Impact of pharmacist-conducted home visits on the outcomes of lipid-lowering drug therapy. Journal of Clinical Pharmacy and Therapeutics, 29, 23 30.
21. Yamada C, Johnson JA, Robertson P, Pearson G, Tsuyuki RT (2005) Long-term impact of a community pharmacist intervention on cholesterol levels in patients at high risk for cardiovascular events: extended follow-up of the second study of cardiovascular risk intervention by pharmacists (SCRIP-plus). Pharmacotherapy, 25, 110 115.
22. Palmieri J, Redline S, Morita R (2005) Goal attainment in patients referred to a telephone-based dyslipidemia program. American Journal of Health-System Pharmacy, 62, 1586 1591.
23. Paulos CP, Nygren CE, Celedon C, Carcamo CA (2005) Impact of a pharmaceutical care program in a community pharmacy on patients with dyslipidemia. Annals of Pharmacotherapy, 39, 939 943.
24. McCord AD (2006) Clinical impact of a pharmacist-managed diabetes mellitus drug therapy management service. Pharmacotherapy, 26, 248 53.
25. GESICA Investigators (2005) Randomized trial of telephone intervention in chronic heart failure: DIAL trial. British Medical Journal, 331, 425 27.
26. Lindenmeyer A, Hearnshaw H, Vermeire E, Van Royen P, Wens J, Biot Y (2006) Interventions to improve adherence to medication in people with type 2 diabetes mellitus: a review of the literature on the role of pharmacists. Journal of Clinical Pharmacy and Therapeutics, 31, 409 419.
27. Choe HM, Mitrovich S, Dubay D, Hayward RA, Krein SL, Vijan S (2005) Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: a randomized controlled trial. American Journal of Managing Care, 11, 253 260.
28. Ragucci KR, Fermo JD, Wessell AM, Chumney EC (2005) Effectiveness of pharmacist-administered diabetes mellitus education and management services. Pharmacotherapy, 25, 1809 1816.
29. Kiel PJ, McCord AD (2005) Pharmacist impact on clinical outcomes in a diabetes disease management program via collaborative practice. Annals of Pharmacotherapy, 39, 1828 32.
30. Odegard PS, Goo A, Hummel J, Williams KL, Gray SL (2005) Caring for poorly controlled diabetes mellitus: a randomized pharmacist intervention. Annals of Pharmacotherapy, 39, 433 440.